Literature DB >> 17075377

Up-regulation of functional CXCR4 expression on human lymphocytes in sepsis.

Ziqiang Ding1, Song H Jia, John C Marshall, Gregory P Downey, Thomas K Waddell.   

Abstract

OBJECTIVE: Lymphocyte dysfunction has been documented in sepsis, and evidence suggests that lymphocyte infiltration contributes to tissue injury. The purpose of this study was to examine chemokine receptor expression and function in lymphocytes from septic patients and healthy donors.
DESIGN: Observational study of septic patients and laboratory investigation of normal controls.
SETTING: Tertiary care intensive care unit. PATIENTS AND
SUBJECTS: Nine critically ill patients fulfilling criteria for the systemic inflammatory response syndrome and with a Sepsis Score of >/=3 were included in this study. Lymphocytes were also obtained from healthy volunteers.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The total number of circulating leukocytes in septic patients was markedly increased; however, lymphocyte counts were decreased. Chemokine receptor expression on lymphocytes was examined by flow cytometry. CXCR4 expression on lymphocytes from septic patients was increased whereas CCR5 was decreased and CCR7 was unchanged. Lipopolysaccharide stimulation of normal lymphocytes increased CXCR4 expression but decreased CCR5 and did not change CCR7 expression. This lipopolysaccharide-stimulated CXCR4 expression required 20 hrs of stimulation and was accompanied by increased messenger RNA. Lymphocytes from septic patients or after lipopolysaccharide treatment demonstrated enhanced actin polymerization and migration in response to CXCL12. Taken together, sepsis and lipopolysaccharide up-regulated CXCR4 expression and enhanced lymphocyte activation and migration in response to CXCL12.
CONCLUSIONS: Blocking CXCR4 and CXCL12 function may provide a novel therapeutic method for controlling systemic inflammation and tissue injury in sepsis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17075377     DOI: 10.1097/01.CCM.0000247719.37793.43

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  11 in total

Review 1.  CXCL12 in control of neuroinflammation.

Authors:  Miljana Momcilović; Marija Mostarica-Stojković; Djordje Miljković
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 2.  Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology.

Authors:  Meizhang Li; Richard M Ransohoff
Journal:  Prog Neurobiol       Date:  2007-11-26       Impact factor: 11.685

3.  Preexisting malignancy abrogates the beneficial effects of CXCR4 blockade during sepsis.

Authors:  Wenxiao Zhang; Deena B Chihade; Jianfeng Xie; Ching-Wen Chen; Kimberly M Ramonell; Zhe Liang; Craig M Coopersmith; Mandy L Ford
Journal:  J Leukoc Biol       Date:  2020-01-27       Impact factor: 4.962

4.  Lymphocyte integrin expression differences between SIRS and sepsis patients.

Authors:  D S Heffernan; S F Monaghan; Alfred Ayala
Journal:  Ir J Med Sci       Date:  2016-10-31       Impact factor: 1.568

5.  CXCR4 antagonist AMD3100 attenuates colonic damage in mice with experimental colitis.

Authors:  Xian-Ming Xia; Fang-Yu Wang; Wen-An Xu; Zhen-Kai Wang; Jiong Liu; You-Ke Lu; Xin-Xin Jin; Heng Lu; Yun-Zhu Shen
Journal:  World J Gastroenterol       Date:  2010-06-21       Impact factor: 5.742

6.  Development of CXCR4 modulators by virtual HTS of a novel amide-sulfamide compound library.

Authors:  Renren Bai; Qi Shi; Zhongxing Liang; Younghyoun Yoon; Yiran Han; Amber Feng; Shuangping Liu; Yoonhyeun Oum; C Chris Yun; Hyunsuk Shim
Journal:  Eur J Med Chem       Date:  2016-11-24       Impact factor: 6.514

Review 7.  Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.

Authors:  Hyunsuk Shim; Shinya Oishi; Nobutaka Fujii
Journal:  Semin Cancer Biol       Date:  2008-11-25       Impact factor: 15.707

8.  CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis.

Authors:  Xian-Ming Xia; Fang-Yu Wang; Ju Zhou; Kai-Feng Hu; Su-Wen Li; Bing-Bing Zou
Journal:  PLoS One       Date:  2011-11-03       Impact factor: 3.240

9.  AQP5-1364A/C polymorphism and the AQP5 expression influence sepsis survival and immune cell migration: a prospective laboratory and patient study.

Authors:  Katharina Rump; Matthias Unterberg; Lars Bergmann; Agnes Bankfalvi; Anil Menon; Simon Schäfer; André Scherag; Zainab Bazzi; Winfried Siffert; Jürgen Peters; Michael Adamzik
Journal:  J Transl Med       Date:  2016-11-21       Impact factor: 5.531

10.  Endothelium dependent vasomotion and in vitro markers of endothelial repair in patients with severe sepsis: an observational study.

Authors:  Sabrina H van Ierssel; Emeline M Van Craenenbroeck; Vicky Y Hoymans; Christiaan J Vrints; Viviane M Conraads; Philippe G Jorens
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.